Falecalcitriol

1. Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial. Clin Nephro 2. Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y. Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambul 3. Iwao Y, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R. Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemo 4. Morii H. Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidismClin Calcium. 2005 Jan;15(1):29-33. 5. Ohtsuka N, Urayama K. Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3.Nihon Yakurigaku Zasshi. 2002 Dec;120(6):427-36. 6. Jean-Pierre B?gu?, Dani?le Bonnet-Delpon.Recent advances (1995-2005) in fluorinated pharmaceuticals based on natural products. Journal of Fluorine Chemistry.Volume 127, Issue 8, August 2006, Pages 992-1012